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Summary 
Antigen-presenting cells (APC) transfected with a construct encoding the hen egg-white lysozyme 
(HEL)  amino  acid  sequence 1-80  constitutively present  HEL  peptides  complexed to  major 
histocompatibility complex (MHC) class II molecules to specific T  cell hybridomas, indicating 
that endogenous cellular antigens can be efficiently presented to class II-restricted T cells. Here 
we show that exogenous peptide competitors added to HEL-transfected APC can inhibit the 
presentation of endogenous HEL peptides to class II-restricted T cells. The inhibition is specific 
for the class II molecule binding the competitor peptide, and it affects to the same extent presentation 
of exogenous or endogenous HEL peptides.  These results, demonstrating that an exogenous 
competitor can inhibit class II-restricted T cell activation induced by endogenous as well as exogenous 
antigen, suggest lack of strict compartmentalization between endogenous and exogenous pathways 
of antigen presentation. Since autoreactive T cells may recognize endogenous, as well as exogenous 
antigens,  the results have implications for the treatment of autoimmune diseases by MHC blockade. 
T  cells  recognize antigen as peptides bound to MHC- 
encoded molecules on the surface of APC (1). Two classes 
of MHC molecules are involved in antigen presentation to 
T  cells:  class I  molecules, expressed on the surface of the 
majority of nucleated cells  (2),  and class II molecules, ex- 
pressed mainly on B cells, macrophages, and dendritic cells 
(3). Although class I and class II MHC molecules appear to 
have similar antigen-binding sites (4),  they are loaded with 
peptides at different intracellular locations (5-8) and interact 
with different T cell populations, CD8 + or CD4 +, respec- 
tively (9). Two separate pathways of antigen processing and 
presentation have been proposed, leading to selective associa- 
tion of peptides from endogenous cellular antigens to class 
I molecules and of peptides from exogenous protein antigens 
to class II MHC molecules (10). However, peptides derived 
from endogenous cellular antigens can bind to class II mole- 
cules and be presented to T  cells  (11-14). 
Here we demonstrate inhibition by an exogenous MHC- 
binding competitor of class II-restricted T cell activation in- 
duced by endogenously derived antigenic peptides,  suggesting 
lack of strict compartmentalization between the two pathways. 
These results imply that administration of exogenous class 
II blockers may also inhibit presentation of endogenous an- 
tigens, including those potentially able to activate class II-re- 
stricted autoreactive T cells leading to MHC-linked autoim- 
mune diseases. 
Materials and Methods 
Antigens.  The synthesis, purification, and analysis  of HEL pep- 
tides have been previously described (15). 
Cell Cultures.  The establishment of class II-restricted,  HEL 
specific T cell hybridomas has been described (15). Cultures con- 
taining 5  x  104 T hybridoma cells and the indicated number of 
APC were set up in microtiter plates with or without antigen in 
0.2 ml of RPMI 1640 (Gibco Laboratories, Grand Island, NY) sup- 
plemented with 2 mM t-glutamine, 50 gM 2-ME, 50 gg/ml gen- 
tamicin, and 10% FCS (Seromed). After 24 h of culture,  50-#1 
aliquots of supematant were assayed  for the presence  ofT cell growth 
factors by [JH]thymidine incorporation  in 104 CTLL cells. 
HEL, transfected APC.  The preparation ofplasmids, constructs, 
and transfected cells are described in detail elsewhere (Moreno, J., 
D. A. A. Vignali, F. Nadimi, S. Fuchs, L. Adorini, and G. J. H~im- 
merling, manuscript submitted for publication). Briefly, exons 1 
and 2 of HEL were ligated to exons 5, 6, 7, and 8 of H-2K  k, and 
the entire hybrid sequence was ligated into the plasmid pHBAPr- 
1-neo, containing  the human B-actin promoter,  to  obtain  the 
construct pJAM2B-neo. LK-35.2 and A20 cells were transfected 
with linearized plasmid DNA and selected in medium containing 
G418. A20 cells transfected with genomic I-Aa  k and I-A~  b clones 
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were selected  for I-Aakfl  b expression and cloned by FACS  |  (Becton 
Dickinson & Co., Mountain View, CA) at one cell/well. LK-35.2 
cells transfected with pJAM2B-neo were cloned by limiting dilu- 
tion. Clones were screened  for their ability to stimulate appropriate 
class II-restricted,  HEbspecific T cell hybridomas in the absence 
of exogenous HEL. 
Results and Discussion 
We tested the presentation of an endogenous cellular an- 
tigen to class II-restricted T cells by transfecting APC with 
a construct containing the first two exons of HEL, coding 
for HEL residues 1-80, linked to the transmembrane and cy- 
toplasmic exons of the K k gene, all under the B-actin pro- 
moter (Moreno et al., manuscript submitted for publication). 
This construct, (HEL[1-80]-K~),  was transfected in LK-35.2 
cells (a B cell hybridoma expressing I-A  k.d and I-E  k,d mole- 
cules) or cotransfected together with genes coding for I-Aol  k 
B  b molecules in A20 cells  (a B cell lymphoma expressing 
bA  d and  I-E  d molecules).  LK-35.2  cells  transfected with 
HEL[1-80]-K  k (LK-HEL) induce, in the absence of added 
antigen, lymphokine production by HEbspecific, class II-re- 
stricted T  cell hybridomas, such as 2B6.3  recognizing the 
HEL peptide 25-43 in association with I-A  k molecules, or 
2G7.1  specific for the HEL peptide 1-18 complexed to I-E  k 
molecules (15), but they fail to activate A.744 cells, a T cell 
hybridoma recognizing the HEL sequence 46-61  together 
with I-Ao~kB  b hybrid class II molecules (16). Conversely, the 
same HEL[1-80]-K  k construct cotransfected together with 
genes coding for I-AcxkB  b molecules in A20 APC (A20.KB- 
HEL cells) fails to activate T cell hybridomas 2B6.3 and 2G7.1, 
but it stimulates A.744 cells (Fig. 1). Lack of cross-stimulation 
of T  cell hybridomas by HEL-transfected APC expressing 
different class II molecules indicates that presentation of en- 
dogenous HEL peptides to T cells is MHC class II restricted. 
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Figure 2,  Ability of exogenous  peptides to inhibit class II-restricted 
presentation of endogenous  antigen  to  T  cells.  LK-HEL cells,  2  x 
104/well (O, A), or A20.KB-HEL cells, 103/well (@), were incubated 
for 24 h with the indicated concentrations of ML 46-62 (a) or Nase 81-100 
(b), then 5  x  104 cells/well ofT hybridomas A.744 (@), 2B6.3 (O), or 
2G7.1  (A) were added, and the culture was continued for a further 24 
h before assessing interleukin production as described in Fig. 1. The con- 
trol responses in the absence of competitor were, in panels a and b, respec- 
tively: 47,807/103,497  (A.744), 174,586/295,143  (2B6.3),  and 162,294/ 
234,866  (2G7.1) cpm. Background incorporation of [3H]thymidine into 
CTLL cells was 251/690  cpm. 
T cell activation depends on the transfected HEL sequence, 
since the T cell hybridoma 2C8.4, recognizing the HEL se- 
quence 112-129 together with I-A  k molecules (15), is not ac- 
tivated by LK-HEL cells  (data not shown). 
We then tested the ability of exogenous peptide compe- 
titors to inhibit the presentation of endogenous antigen to 
class II-restricted T  cells. The mouse lysozyme (ML) pep- 
tide 46-62 binds to I-A  k (17) and to I-Aotk3  b (16), but not 
to I-E  k molecules (18). Incubation of HEL-transfected,  living 
APC with ML 46-62 inhibits, dose-dependently, the activa- 
tion of T cell hybridomas 2B6.3, recognizing the HEL pep- 
tide 25-43 with I-A  k molecules and A.744, recognizing the 
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Figure 1.  Activation of class II-re- 
stricted T cell hybridomas by endoge- 
nous  antigen.  Graded  numbers  of 
different  APC,  LK-35.2  (circle), LK- 
HEL (triangle),  A20.KB (square),  and 
A20.KB-HEL (inverted triangle)  were 
cultured  with  1  /~M  HEL  (closed 
symbols) or without (open symbols),  and 
with 5  x  104 cells/well of the indi- 
cated T  cell hybridomas. After 24 h, 
antigen-specific  T  cell growth factor 
production  was  determined  by  3H- 
labeled thymidine incorporation into 
CTLL cells. Results are expressed  as 
arithmetic mean of cpm from triplicate 
cultures.  Background proliferation of 
CTLL cells was 250 cpm. 
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Figure 3.  Capacity  of the exogenous 
peptide ML 46-62 to inhibit presenta- 
tion to I-A  L and I-Aorta-restricted T 
cells of endogenous and exogenous  an- 
tigenic peptides. The concentration of 
exogenous HEL peptide  required to in- 
duce, in the presence  of  a given  number 
of the appropriate APC, approximately 
the same degree of T cell activation as 
HEI, transfected APC was determined 
in pilot experiments. The indicated con- 
centrations of  MI. 46-62 were  incubated 
in a with 5 x  103 LK-HEL cells (O) 
or with 5 x  103 LK-35.2 cells and 10 
#M HEL peptide 25-43 (0), in b with 
0.5  x  103 A20.KB-HEL cells (O) or 
with 0.5  x  103 A20.KB cells and 1 
/~M peptide HEL 46-61 (0), and in c 
with 2 x  104 LK-HEL cells (O) or with 2 x  104 LK-35.2 cells and 2/xM HEL peptide 1-18 (0). After 24 h of culture, 5 x  104 cells/well of hybrid- 
omas 2B6.3 (a), A.744 (b), and 2G7.1 (c) were added, and after a further 24 h of culture, interleukin production was assessed as described  in Fig. 1. 
Control responses in the absence of competitor were: a, 101,827 (O) and 177,326 (a); b, 24,520 (O) and 19,571 (0); c, 162,294 (O) and 301,171 
(0) cpm. Background incorporation of [3H]thymidine into CTLL cells was 840 cpm. 
HEL peptide 46-61 together with I-Aot~/3  b molecules. ML 
46-62 does not affect recognition of the endogenously de- 
rived peptide corresponding  to the HEL sequence 1-18 by 
the I-Ek-restricted T  cell hybridoma 2G7.1 (Fig.  2 a). These 
results demonstrate  that  an exogenous peptide competitor 
selectively inhibits T cell recognition of endogenous antigen 
restricted by the class II molecules to which the competitor 
binds. ML 46-62 inhibits more efficiently the T cell response 
restricted by I-Aotk~ b than that restricted by I-A  k molecules, 
suggesting that it binds with higher affinity to the former 
class II molecule. Conversely, incubation of HEL-transfected 
APC with the I-Ek-binding peptide Nase 81-100 (19) selec- 
tively inhibits  activation  of the  I-Ek-restricted  T  cell  hy- 
bridoma (Fig. 2 b), further strengthening  the interpretation 
that  inhibition  by exogenous competitors is in fact due to 
competition between peptides for binding to MHC class II 
molecules. The competition for the presentation of endoge- 
nous HEL peptides exerted by the exogenous competitor ML 
46-62 is related to the number of HEL-transfected APC pre- 
senting the endogenous antigen. A 10-fold increase of A20.KB- 
HEL  APC  increases  almost  correspondingly  interleukin 
production by the T cell hybridoma A.744. Accordingly, the 
inhibition induced by the competitor is '~10-fold decreased, 
consistent with  the higher  number of class II endogenous 
HEL peptide complexes present in culture (data not shown). 
To assess the ability of an exogenous competitor to inhibit 
the presentation  of endogenous vs. exogenous antigen,  we 
compared the capacity of ML 46-62 to compete for the pre- 
sentation of endogenous and exogenous HEL peptides. Results 
in Fig.  3  show that  the exogenous competitor ML 46-62 
inhibits equally well the activation induced by endogenous 
or exogenous antigenic peptides of T cell hybridomas 2B6.3 
and A.744, whereas it has no effect on the I-EL-restricted  re- 
sponse of hybridoma  2G7.1. 
These results indicate that  an exogenous competitor can 
inhibit  presentation  to T  cells by MHC class  II molecules 
of peptide antigens not only from exogenous but also from 
endogenous origin,  suggesting lack of strict compartmen- 
talization between endogenous and exogenous pathways of 
antigen presentation.  It is possible that in the case of endog- 
enous HEL presentation,  the competitor either prevents in- 
tracellular loading of class II with peptide or that unloading 
of antigenic peptide and loading of competitor occur. In the 
case of exogenous antigen,  unloading  and reloading could 
take place during endocytosis and recycling of class II mole- 
cules (20),  or at  the call  surface. 
The capacity of an exogenous competitor to inhibit in vitro 
presentation to T cells of endogenous, as well as exogenous, 
antigens suggests that in vivo MHC blockade based on the 
administration  of exogenous peptide competitors (21) could 
inhibit presentation  to class II-restricted T  cells of endoge- 
nous cellular antigens, likely the most relevant in the induc- 
tion  of autoreactive T  cells leading  to HLA-associated au- 
toimmune  diseases. 
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